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Background: Neural tube defects (NTDs) are common birth defects (~1 in 1000 pregnancies in the US and Europe)
that have complex origins, including environmental and genetic factors. A low level of maternal folate is one
well-established risk factor, with maternal periconceptional folic acid supplementation reducing the occurrence of
NTD pregnancies by 50-70%. Gene variants in the folate metabolic pathway (e.g., MTHFR rs1801133 (677 C > T) and
MTHFD1 rs2236225 (R653Q)) have been found to increase NTD risk. We hypothesized that variants in additional
folate/B12 pathway genes contribute to NTD risk.
Methods: A tagSNP approach was used to screen common variation in 82 candidate genes selected from the
folate/B12 pathway and NTD mouse models. We initially genotyped polymorphisms in 320 Irish triads (NTD cases
and their parents), including 301 cases and 341 Irish controls to perform case–control and family based association
tests. Significantly associated polymorphisms were genotyped in a secondary set of 250 families that included 229
cases and 658 controls. The combined results for 1441 SNPs were used in a joint analysis to test for case and
maternal effects.
Results: Nearly 70 SNPs in 30 genes were found to be associated with NTDs at the p < 0.01 level. The ten strongest
association signals (p-value range: 0.0003–0.0023) were found in nine genes (MFTC, CDKN2A, ADA, PEMT, CUBN,
GART, DNMT3A, MTHFD1 and T (Brachyury)) and included the known NTD risk factor MTHFD1 R653Q (rs2236225). The
single strongest signal was observed in a new candidate, MFTC rs17803441 (OR = 1.61 [1.23-2.08], p = 0.0003 for the
minor allele). Though nominally significant, these associations did not remain significant after correction for multiple
hypothesis testing.
Conclusions: To our knowledge, with respect to sample size and scope of evaluation of candidate polymorphisms,
this is the largest NTD genetic association study reported to date. The scale of the study and the stringency of
correction are likely to have contributed to real associations failing to survive correction. We have produced a
ranked list of variants with the strongest association signals. Variants in the highest rank of associations are likely to
include true associations and should be high priority candidates for further study of NTD risk.
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Neural tube defects (NTDs) are one of the most com-
mon birth defects, with a historical prevalence of ~1 in
1000 in the US [1,2]. The NTD rate is now closer to
~5 in 10,000 in areas with folic acid fortification, such
as the US [3] and many European countries [4]. Between
21 and 28 days after conception, the neural plate folds and
closes to form the neural tube; this structure later devel-
ops into the brain and spinal cord. Failure of the neural
tube to close most commonly leads to spina bifida or an-
encephaly, although encephalocele, craniorachischisis and
iniencephaly can also occur [5].
It is known that both environmental and genetic fac-
tors contribute to the development of NTDs. The most
established environmental factor is dietary folate; signifi-
cantly lower levels of folate are observed in mothers with
an NTD pregnancy [6], and periconceptional folate sup-
plementation can reduce the risk of an NTD pregnancy
by up to 75% [7] [8] [9]. There is also growing evidence
of the importance of cobalamin (vitamin B12) in the eti-
ology of NTDs. Like folate, lower vitamin B12 levels
have been reported in mothers with an NTD pregnancy
[6,10-17].
Genetic factors also contribute to NTDs. Compared to
the general population, there is a 10–20 fold higher re-
currence risk to siblings in families with an NTD child
[18-20]. This, combined with the recognition of the im-
portance of maternal folate, has led many groups to
evaluate genetic polymorphisms related to the folate
metabolic pathway as risk factors for NTDs. The best
studied genetic risk factor is a single nucleotide poly-
morphism (SNP) in 5, 10-methylene-tetrahydrofolate re-









Figure 1 Classification Distribution of 82 Selected Candidate Genes. C
(pie chart) are shown. Over half of the genes selected for study are known
vitamin B12 pathway.in the substitution of a valine for an alanine at codon 222
(A222V), leading to a thermolabile isoform of the protein
[21]. A significantly higher frequency of the MTHFR 677
TT genotype has been observed in NTD cases in many
populations (reviewed in [22]). Genetic variants associated
with NTDs have been reported in other genes encoding
folate- and vitamin B12-related proteins, such as methyle-
netetrahydrofolate dehydrogenase (NADP+dependent) 1,
methenyltetrahydrofolate cyclohydrolase, formyltetrahy-
drofolate synthetase (MTHFD1) [23-26], methylenetetra-
hydrofolate dehydrogenase (NADP+dependent) 1-like
(MTHFD1L) [27], dihydrofolate reductase (DHFR) [28,29],
methionine synthase reductase (MTRR) [16,26,30-33], and
the transcobalamin II receptor (TCblR) [34].
As genotyping technology has advanced, the scale of
studies attempting to identify genetic NTD risk factors
has grown from single SNP analyses to simultaneous
evaluation of dozens of variants. Several studies have
evaluated specific candidate polymorphisms with evi-
dence of functional changes and/or disease risk (87 var-
iants in 45 genes, [35]; 48 SNPs in 11 genes [36]; 64
SNPs in 34 genes [37]). In contrast, other studies have
examined all common variation in candidate genes via
tagging SNPs (tagSNPs) in specific genes of interest (118
tagSNPs in 14 folate-related genes [26]; 37 tagSNPs in 6
transcriptional activator genes [38]). In the current
study, we also took the tagSNP approach to evaluate
1441 SNPs in 82 candidate genes for NTD risk.
Results
Common genetic variation in 82 candidate genes
(Figure 1) was tested for association with NTDs. Results







ategories of selected candidate genes (legend) and their distribution
to encode a protein with enzymatic function related to the folate/
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using a subset of samples. In the second stage, SNPs of
interest identified in the initial analysis were then typed
in the complete cohort to maximize the power to detect
an effect, and a wider range of genetic models were ap-
plied to the combined dataset to evaluate the potential
contribution of all SNPs to case or maternal risk of
NTDs.
Initial analyses
The primary sample set (320 NTD case families and 341
controls) was genotyped for 1517 tagging SNPs intended
to capture common genetic variation in 82 candidate
genes related to folate/vitamin B12 metabolism, transport
of folate or vitamin B12, or transcriptional or develop-
mental processes implicated in NTD mouse models
(Table 1). Genotype data was successfully obtained for
1320 SNPs. Four tests of association were performed; two
tests were to detect NTD case risk and two tests were to
detect maternal risk for an NTD pregnancy. There were
203 SNPs in 54 genes that were significant (p< 0.05) by
at least one test of association. A gene-based approach
was used to select SNPs from fifteen genes to be geno-
typed in the secondary sample set. Five genes (mitochon-
drial folate transporter/carrier (MFTC), megalin (LRP2,
low density lipoprotein receptor-related protein 2), DNA
(cytosine-5-)-methyltransferase 3 beta (DNMT3B), phos-
phatidylethanolamine N-methyltransferase (PEMT), and
euchromatic histone-lysine N-methyltransferase (EHMT1))
contained at least one SNP that was positive for both
tests of a case effect or both tests of a maternal effect.
An additional four genes (5-methyltetrahydrofolate-
homocysteine methyltransferase 1 (MTR), cubilin (CUBN,
intrinsic factor-cobalamin receptor), T (Brachyury homo-
log (mouse)), and AT rich interactive domain 1A
(ARID1A)) contained more than five SNPs significant for
any of the four tests of association. The remaining six
genes (adenosine deaminase (ADA), ferritin, heavy poly-
peptide 1 (FTH1), cystathionase (CTH), peptidyl arginine
deiminase, type IV (PADI4), low density lipoprotein
receptor-related protein 6 (LRP6), and serine hydroxy-
methyltransferase 1 (SHMT1)) were selected based on a
combination of factors, including the number of positive
SNPs, their level of significance, and biological plausibility.
Any SNP in these genes significant by any of the four tests
of association (Table 2) was selected for genotyping in the
secondary sample set (258 additional case families and
658 additional controls).
Combined analyses
In the combined analyses each SNP was evaluated for
contributing to NTD risk by twelve association tests:
case and maternal effects were each evaluated using
three case–control (or mother-control) tests and threefamily-based tests (see Methods). There were 68 SNPs
in 30 genes that showed an association at the p < 0.01
level by any of the twelve tests (Table 3). Of these,
twelve genes contained a single associated SNP. The
remaining 56 SNPs were found in 18 genes. Not all
associations were independent. Areas of interest were
covered by tagSNPs as well as additional SNPs for
physical coverage; as a result there were seven SNP
pairs in this set with a linkage disequilibrium (LD) rela-
tionship above the threshold (r2≥ 0.8) selected for tag-
ging in this study (Figure 2, ARID1A_rs11247593 and
ARID1A_rs11247594,CUBN_rs7070148 andCUBN_rs2273737,
GART_rs2070388 and GART_rs4817580, MFTC_rs17803441
and MFTC_rs3134260, MTHFR_rs17367504 and MTHFR_
rs17037425, MTR_rs10733117 and MTR_rs10925260, and
PEMT_rs4646402 and PEMT rs1108579). Notably, for
many genes, the associated SNPs occur in the same haplo-
type block (solid spine of LD based on D’ relationships),
implying a single association signal for that gene (Figure 2,
GART, COMT, MFTC, MTHFR, ARID1A, MTR, FOLH1,
MTHFD1, PEMT, RAI1, ENOSF1). A single signal prob-
ably also accounts for the significant SNP pairs seen in
PDGFRA (D’= 0.65) and CDKN2A (D’=0.79). Genes exhi-
biting more than one independent SNP association in-
clude FTCD (D’= 0.10), MTHFD1L (two separate
haplotype blocks and two SNPs, D’≤ 0.57), CUBN (one
haplotype block and a SNP, D’≤ 0.20), ALDH1A2
(D’=0.13) and ADA (a weak haplotype block and a SNP,
D’≤ 0.19).
We ranked SNPs by the lowest p-value for any test,
accounting for relatedness to other highly significant
SNPs. The nine genes exhibiting the 10 strongest associ-
ation signals were: MFTC, CDKN2A, ADA, PEMT,
CUBN, GART, ADA, DNMT3A, MTHFD1 and T (Bra-
chyury) (Table 4). MFTC, ADA, PEMT and CUBN con-
tained more than one significant SNP, and ADA showed
evidence of two independent association signals.
SNPs in MFTC, PEMT and ADA account for seven of
the top ten SNPs (Table 4). In MFTC, these two SNPs
(rs17803441 and rs3134260) are essentially in perfect LD
(D’= 1.0, r2 = 0.99). As expected, they yielded very similar
evidence of NTD risk in a continuous model of logistic
regression (rs17803441: OR= 1.61 [1.23-2.08], p = 0.0003,
Risk Allele Frequency (RAF) = 0.07; rs3134260: OR= 1.56
[1.22-2.04], p = 0.0006, RAF= 0.07), as well as a recessive
model of logistic regression (rs17803441: OR= 1.59
[1.19-2.08], p = 0.0013; rs3134260: OR= 1.54 [1.18-2.04],
p = 0.0021). There are a total of five highly significant
(p < 0.01) MFTC SNPs and they are all consistent with a
case effect. MFTC rs10112450 is significant by the trans-
mission disequilibrium test (TDT, GRR=1.42,
p = 0.0065, RAF = 0.79), and the remaining MFTC SNPs
(rs1865855 and rs750606) show evidence of NTD risk to
the case by logistic regression with a continuous or
Table 1 Candidate Genes Selected for Evaluation of Common Genetic Variation as NTD Risk Factors
Gene Description No. SNPs Category*
ADA Adenosine deaminase 20 1 C
AHCY S-Adenosylhomocysteine hydrolase 4 1 C
ALDH1A2 Aldehyde dehydrogenase 1 family, member A2 24 1A
ALDH1L1 Aldehyde dehydrogenase 1 family, member L1 35 1A
AMN Amnionless homolog (mouse) 5 4
ARID1A AT rich interactive domain 1A (SWI- like) 20 3
ATIC 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase 9 1A
BAT8 HLA-B associated transcript 8 8 5
BHMT Betaine-homocysteine methyltransferase1 12 1 C
BHMT2 Betaine-homocysteine methyltransferase2 2 1 C
CCL2 Chemokine (C-C motif) ligand 2 (Monocyte chemoattractant protein 1) 6 5
CDKN2A Cyclin-dep. kinase inhibitor 2A (melanoma, p16, inhibitor CDK4, P14arf) 10 3
CITED2 Cbp/p300-interacting transactivator, w. Glu/Asp-rich C-teminal domain, 2 6 3
COMT Catechol-O-methyltransferase 16 1 C
CREBBP CREB binding protein (Rubinstein-Taybi syndrome) 22 3
CTH Cystathionase (cystathionine gamma-lyase) 16 1 C
CUBN Cubilin (intrinsic factor-cobalamin receptor) 141 2B
CYB5R2 Cytochrome b5 reductase2 12 1A
DHFR Dihydrofolate reductase 10 1A
DMGDH Dimethylglycine dehydrogenase 24 1A
DNMT1 DNA cytosine 5 methyltransferase1 7 1 C
DNMT3A DNA cytosine 5 methyltransferase3a 26 1 C
DNMT3B DNA cytosine 5 methyltransferase3b 19 1 C
EHMT1 euchromatic histone methyltransferase 1 20 1 C
ENOSF1 Enolase superfamily member 1 22 1A
EP300 E1A binding protein p300 10 3
EPHA3 EPH (ephrin) receptor A3 45 4
FOLH1 Folylpolyglutamate hydrolase (gamma-glutamyl hydrolase, Glutamate carboxypeptidase II) 9 2A
FOLR1 Folate receptor alpha 7 2A
FOLR2 Folate receptor 2 (fetal) 5 2A
FOLR3 Folate binding protein gamma and g 8 2A
FPGS Folylpolyglutamate synthase 4 2A
FTCD Formiminoglutamate formiminotransferase-cyclodeaminase 17 1A
FTH1 Ferritin heavy chain 11 1A
GART Phosphoribosylglycinamide formyltransferase/synthetase, phosphoribosylaminoimidazole
synthetase
10 1A
GGH Lysosomal gamma-glutamylhydrolase 11 1A
GIF Intrinsic factor (gastric IF) 4 2A
GNMT Glycine N-methyltransferase 5 1 C
GRIK5 Glutamate receptor, ionotropic, kainate 5 4 4
HIF1A Hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix trx factor) 11 3
HRMT1L2 PRMT1 (Protein arginine methyltransferase 1) HMT1 hnRNA Mtase-like2 8 1 C
HRMT1L3 PRMT3, HMT1 hnRNA Mtase-like3 30 1 C
ICMT Isoprenylcysteine carboxyl methyltranferase 7 1 C
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Table 1 Candidate Genes Selected for Evaluation of Common Genetic Variation as NTD Risk Factors (Continued)
IRF6 Interferon regulatory factor 6 11 3
LRP2 Megalin, low density lipoprotein-related protein 2 75 2B
LRP6 Low density lipoprotein receptor-related protein 6 24 2B
MAT1A Methionine adenosyltransferase 1 19 1 C
MAT2A Methionine adenosyltransferase II alpha 4 1 C
MAT2B Methionine adenosyltransferase II beta 9 1 C
MFTC Mitochondrial folate transporter/carrier 11 2A
MMAA Methylmalonic aciduria (cobalamin deficiency) type A 14 1B
MMAB AdoB12 adenosyltransferase, methylmalonic aciduria type B 7 1B
MMACHC Methylmalonic aciduria cblC type with homocystinuria (CblC compl group) 8 1B
MTHFD1 Methylenetetrahydrofolate dehydrogenase (NADP+dependent) 1, methenyltetrahydrofolate
cyclohydrolase, formyltetrahydrofolate synthetase (cytosolic)
20 1A
MTHFD1L Methylenetetrahydrofolate dehydrogenase (NADP+dependent) 1-like (Formyltetrahydrofolate
synthetase domain containing 1) (mitochondrial)
115 1A
MTHFD2 Methylenetetrahydrofolate dehydrogenase (NADP+dependent) 2, methenyltetrahydrofolate
cyclohydrolase (mitochondrial)
6 1A
MTHFR Methylenetetrahydrofolate reductase 19 1A
MTHFS 5,10-Methenyltetrahydrofolate synthetase 18 1A
MTR Methionine synthase 20 1B
MTRR Methionine synthase reductase 23 1B
NDOR1 NADPH dependent diflavin oxidoreductase 1 2 1A
NNMT Nicotinamide N-methyltransferase 11 1 C
NOS3 Nitric oxide synthase 3 (endothelial cell) 13 5
PADI4 peptidyl arginine deiminase, type IV 28 1 C
PAX3 Paired box gene 3 (Waardenburg syndrome 1) 51 3
PCMT1 Protein-L-isoaspartate (D-aspartate) O-methyltransferase 7 1 C
PDGFRA Platelet-derived growth factor receptor alpha 17 4
PEMT phosphatidylethanolamine N-methyltransferase 14 1 C
PGM2 pgm2 methionine synthase interacting protein 19 1B
PRMT8 Protein arginine methyltransferase 8 54 1 C
RAI1 Retinoic acid induced 1 13 4
SHMT1 Serine hydroxymethyl transferase (C) 12 1A
SHMT2 Serine hydroxymethyl transferase (M) 4 1A
SLC19A1 Reduced folate carrier 4 2A
T (Brachyury) T, brachyury homolog (mouse) 20 4
TCblR Transcobalamin II receptor 5 2B
TCN1 Transcobalamin I 2 2B
TCN2 Transcobalamin II 20 2B
TFAP2A Transcription factor AP-2 alpha (activating enhancer binding protein 2 alpha) 16 3
TK1 Thymidine kinase 1, soluble 12 1A
TP53 Tumor protein 53 (Li-Fraumeni syndrombe) 8 3
TYMS Thymidylate synthase 4 1A
*Category Key: 1A, Enzymatic (folate); 1B, Enzymatic (B12); 1 C, Enzymatic (methylation); 2A, Transport (folate); 2B, Transport (B12); 3, Transcription; 4, Development;
5, Other.
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rs2428735 PADI4 0.0006 0.2801 0.0229 0.4043
rs942459 PADI4 0.0089 0.3841 0.1002 .*
rs12743862 ARID1A 0.1030 0.0314 0.9124 .
rs12729444 ARID1A 0.1068 0.0314 0.9124 .
rs12726081 ARID1A 0.1030 0.0314 0.9124 .
rs12726287 ARID1A 0.1030 0.0314 0.9276 .
rs11247593 ARID1A 0.0208 0.1294 0.1815 0.1383
rs11247594 ARID1A 0.0257 0.1580 0.2126 0.1331
rs12752833 ARID1A 0.1030 0.0314 0.9124 .
rs12735646 ARID1A 0.1030 0.0290 0.9124 .
rs12737946 ARID1A 0.1030 0.0314 0.9124 .
rs12731749 ARID1A 0.0862 0.0201 0.8813 .
rs11247596 ARID1A 0.7022 0.0311 0.9123 0.9708
rs12733999 CTH 0.0277 1.0000 0.0077 .
rs10889869 CTH 0.9408 0.0436 0.2582 0.9918
rs12723350 CTH 0.0472 0.6803 0.0120 0.0572
rs16834388 MTR 0.1070 0.0225 0.9177 0.8117
rs10733117 MTR 0.1604 0.0207 0.5363 0.1956
rs10925238 MTR 0.0503 0.0139 0.9512 0.5724
rs4077829 MTR 0.0921 0.0170 0.7931 0.6494
rs12060570 MTR 0.0602 0.0201 0.9373 0.6843
rs2789352 MTR 0.2535 0.0348 0.7505 0.1245
rs7367859 MTR 0.2355 0.0444 0.5437 0.0571
rs10925260 MTR 0.1262 0.0328 0.8485 0.1713
rs2853522 MTR 0.1080 0.0449 0.8826 0.1600
rs2853523 MTR 0.2127 0.0418 0.7770 0.0594
rs3944004 LRP2 0.3963 0.0048 0.5667 0.2170
rs4667593 LRP2 0.7913 0.0087 0.3028 0.7203
rs16856530 LRP2 0.1458 0.4352 0.0396 0.7874
rs2024481 LRP2 0.9568 0.0087 0.2889 0.7601
rs10490131 LRP2 0.4348 0.0140 0.8093 0.8201
rs4668123 LRP2 0.1564 0.9379 0.0487 0.9494
rs2268373 LRP2 0.0338 0.0229 0.0718 0.4172
rs11886219 LRP2 0.0491 0.3924 0.0034 .
rs2268365 LRP2 0.6858 0.0312 0.6914 0.8866
rs2673164 LRP2 0.5967 0.7656 0.4009 0.0231
rs700550 LRP2 0.4767 0.2507 0.7529 0.0383
rs853988 LRP2 0.8386 0.6872 0.2807 0.0048
rs2673177 LRP2 0.0095 0.5791 0.0015 0.0279
rs10199676 LRP2 0.0075 0.7290 0.0213 0.9036
rs2389557 LRP2 0.0336 0.6507 0.1005 0.4636
rs16856843 LRP2 0.0075 0.9055 0.0133 0.9035
rs10806845 T (Brachyury) 0.0399 0.6331 0.0010 0.3100
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Table 2 SNPs Selected for Study in the Combined NTD Cohort (Continued)
rs3127441 T (Brachyury) 0.0485 0.6215 0.0043 0.8873
rs12200529 T (Brachyury) 0.5867 0.7758 0.0278 0.2407
rs16898752 T (Brachyury) 0.1443 1.0000 0.0412 0.2063
rs7753771 T (Brachyury) 0.5378 1.0000 0.0384 .
rs1001978 T (Brachyury) 0.5378 1.0000 0.0384 .
rs3099280 T (Brachyury) 0.9972 0.5149 0.0199 0.1406
rs4512347 MFTC 0.0344 0.6473 0.2789 .
rs10112450 MFTC 0.1575 0.0196 0.4726 0.3474
rs17803441 MFTC 0.0016 0.0115 0.2911 0.2838
rs3134260 MFTC 0.0016 0.0086 0.2513 0.2919
rs4876902 EHMT1 0.4872 0.0595 0.6710 0.9049
rs4526432 EHMT1 0.0433 0.0251 0.5323 0.4040
rs10752062 CUBN 0.2564 0.8216 0.0254 0.1471
rs17139378 CUBN 0.2113 0.6780 0.0086 0.1051
rs7100290 CUBN 0.4039 0.0269 0.6692 .
rs1276720 CUBN 0.2147 0.0422 0.5445 0.0714
rs1276721 CUBN 0.1737 0.0206 0.5381 0.2471
rs11254284 CUBN 0.4198 0.7175 0.0474 0.0548
rs11254313 CUBN 0.4354 0.4206 0.0277 0.3041
rs12258009 CUBN 0.7700 0.1582 0.6214 0.7119
rs17431655 CUBN 0.1453 0.8474 0.0459 .
rs17139663 CUBN 0.0407 0.8864 0.0579 0.5552
rs11254339 CUBN 0.0490 0.7928 0.0838 0.8621
rs1801228 CUBN 0.1118 0.8474 0.0356 .
rs12254816 CUBN 0.5285 0.6670 0.0407 0.1765
rs7899751 CUBN 0.4747 0.8386 0.0433 0.1183
rs11254375 CUBN 0.7142 0.6682 0.5854 0.0332
rs7070148 CUBN 0.1447 0.9013 0.0029 0.2028
rs2273737 CUBN 0.1136 0.9042 0.0064 0.3337
rs7096079 CUBN 0.0202 0.8897 0.0432 0.3447
rs2073588 FTH1 0.2129 0.0046 0.9390 .
rs17156616 FTH1 0.5455 0.0127 0.8668 .
rs195445 FTH1 0.9840 0.3738 0.8436 0.7908
rs7957531 LRP6 0.4835 0.9068 0.0407 0.2288
rs10845493 LRP6 0.1614 0.0149 0.9106 0.7491
rs17302049 LRP6 0.4464 0.0242 0.8904 0.9593
rs1181334 LRP6 0.2935 0.0211 0.9466 0.9000
rs12309338 LRP6 0.7156 0.6056 0.0329 .
rs3760183 PEMT 0.0146 0.0111 0.2960 .
rs16961845 PEMT 0.2442 0.8788 0.0043 .
rs4646342 PEMT 0.4687 0.6714 0.7126 0.0351
rs2350631 PEMT 0.0641 0.6803 0.0181 0.3410
rs9910090 SHMT1 0.0342 0.1508 0.1370 0.7042
rs9901160 SHMT1 0.5153 0.0153 0.9278 0.4380
rs4911263 DNMT3B 0.0686 0.8332 0.0145 0.0475
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Table 2 SNPs Selected for Study in the Combined NTD Cohort (Continued)
rs6058896 DNMT3B 0.0460 0.0016 0.5438 .
rs447833 ADA 0.0832 0.0090 0.3777 0.6497
rs2299686 ADA 0.4258 0.7269 0.0391 0.2794
rs427483 ADA 0.3645 0.5276 0.0275 0.5681
rs6094017 ADA 0.1869 0.5169 0.0088 0.6004
* (.) = Failure to converge (no result).
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SNPs fall in the same haplotype block (D’ > 0.96), it is
likely there is a single variant in this region responsible
for the association signals.
Three SNPs in PEMT were in the top ten SNPs, and
two of these are in high linkage disequilibrium (rs1108579
and rs4646402; D’= 1.0, r2 = 0.809). These SNPs also yield
very similar evidence of NTD risk by TDT (rs1108579:
GRR=1.47, p = 0.0006, RAF=0.52; rs4646402: GRR=
1.43, p = 0.0009, RAF= 0.57). PEMT rs11656215 is less
strongly linked to these SNPs (r2 < 0.6), and shows associ-
ation with NTD risk by TDT (GRR=1.35, p = 0.0053,
RAF=0.49) and by log-linear analysis of a recessive model
(GRR=1.68 [1.24-2.28], p = 0.0008). A fourth highly sig-
nificant SNP was found in the maternal analysis
(rs16961845). It shows evidence of maternal risk in a re-
cessive model of log-linear analysis (GRR=1.92 [1.18-
3.11], p = 0.0082), as well as recessive (p < 0.0048) and
continuous (p < 0.0072) models of logistic regression. By
r2 measures of LD, this SNP is the least related to the
other three SNPs (r2 < 0.08), although all four of these
SNPs fall in the same haplotype block (Figure 2).
Lastly, three SNPs in ADA were among the ten SNPs
with the lowest p values. They show evidence of LD by D’
(≥0.82) but less so by r2 (≤0.54). These three SNPs are all
significantly associated with a maternal effect by logistic
regression of a continuous model (rs2299686: OR=1.30
[1.11-1.52], p = 0.0010, RAF= 0.45; rs427483: OR=1.28
[1.10-1.52], p = 0.0018, RAF= 0.33; rs406383: OR=1.33
[1.12-1.58], p = 0.0012, RAF=0.25). Three other SNPs in
ADA (rs6031682, rs452159 and rs6094017) also showed a
highly significant association with a maternal effect in a
continuous model of logistic regression (p < 0.0059). All
six SNPs were highly significant (p< 0.01) for association
with maternal risk in either a recessive model (rs406383,
p = 0.0021) or dominant model (the other five SNPs,
p≤ 0.0063) of logistic regression. Additionally, ADA
rs6031682 shows association with case risk in a continu-
ous model of logistic regression (1.38 [1.10-1.73],
p = 0.0052, RAF=0.84). These six SNPs do not appear to
be strongly linked; no haplotype blocks (solid spine of LD)
larger than two SNPs were identified. It appears that
rs6031682 is clearly outside of a degraded haplotype block
consisting of the other five SNPs.CUBN was the only other gene with more than one
SNP found in the ten most strongly associated signals.
CUBN rs7070148 and CUBN rs2273737 were both sig-
nificant for association with maternal risk in a continu-
ous model of logistic regression (OR= 1.64 [1.22-2.17],
p = 0.0010, RAF= 0.90 and OR= 1.54 [1.18-2.04],
p = 0.0021, RAF= 0.89, respectively). These SNPs are
highly linked (D’= 0.935, r2 = 0.823). There are three
other highly significant (p < 0.01) SNPs in CUBN. Two
other SNPs in the same haplotype block with CUBN
rs7070148 and CUBN rs2273737 (rs1801222 and
rs11254375, D’ < 0.76) also showed an association with
maternal effects. A third SNP, CUBN rs11591606, is out-
side this block (D’ < 0.20) and is associated with maternal
risk in a dominant model of logistic regression (OR=
4.15 [1.51-11.39], p = 0.0058, RAF = 0.17).
Correction for multiple testing was performed for
three of the twelve tests of association. No adjusted p-
value was found to remain significant, and no further
correction was performed.
Discussion
This study represents a new scale of evaluation of gen-
etic contribution to NTD risk. Common variants in 82
biologically plausible candidate genes were tested for as-
sociation with NTDs in a large Irish population. Seven-
teen variants in nine genes account for the ten most
significant associations observed. CDKN2A, GART,
DNMT3A, MTHFD1 and T (Brachyury) contained a sin-
gle SNP among the ten lowest p-values observed for all
tests. In contrast, MFTC, ADA, PEMT, and CUBN each
contained more than one such SNP. This seems to be
due to strong LD relationships between the associated
SNPs. The only exception is in ADA, which shows evi-
dence of two strong, unrelated association signals.
ADA (adenosine deaminase) converts adenosine to in-
osine by removal of an amino group. Deficiency in this
enzyme causes severe combined immunodeficiency dis-
ease (SCID), which is characterized by compromise of
both T cells and B cells. Interestingly, ADA activity was
significantly elevated in a study of 68 pregnant women
carrying a fetus with a central nervous system malforma-
tion [39]; of these women, 17 had a spina bifida preg-
nancy. Consistent with this, six unrelated (r2 < 0.70),
Table 3 p-values for Evaluated SNPs Showing Association (p < 0.01) with NTDs
Gene/SNP TDT LL CC Rec LL CC Dom LR CC Cont LR CC Rec LR CC Dom LL Mat 2DOF LL Mat Rec LL Mat Dom LR MC Cont LR MC Rec LR MC Dom
*MFTC rs17803441 0.0300 0.1456 0.0098 0.0003 0.0013 0.0146 0.4634 0.6352 0.2195 0.1928 0.2373 0.3535
CDKN2A rs3218009 0.1284 0.9996 0.1786 0.0426 0.9775 0.1009 .** 0.2734 0.0004 0.3032 0.5724 0.3296
*ADA rs2299686 0.8288 0.7819 0.5289 0.2994 0.3991 0.3958 0.2165 0.1923 0.1183 0.0010 0.0479 0.0005
*PEMT rs4646402 0.0009 0.1861 0.0005 0.1374 0.3728 0.1348 0.7219 0.5709 0.7630 0.7482 0.5319 0.9693
*MFTC rs3134260 0.0225 0.1301 0.0059 0.0006 0.0021 0.0141 0.4213 0.4460 0.2195 0.2102 0.2594 0.3484
*PEMT rs1108579 0.0006 0.0463 0.0014 0.0462 0.0482 0.1846 0.7076 0.4098 0.8059 0.9490 0.9274 0.9873
*PEMT rs11656215 0.0053 0.0008 0.3818 0.2070 0.1461 0.5412 0.7689 0.5639 0.8703 0.8211 0.3273 0.5520
*CUBN rs7070148 0.4864 0.4012 0.6033 0.0909 0.8065 0.0746 0.4458 0.4235 0.2551 0.0010 0.1735 0.0013
*ADA rs406383 0.0590 0.0311 0.3102 0.8420 0.7244 0.6858 0.1205 0.4468 0.0398 0.0012 0.0021 0.0136
*GART rs2070388 0.0012 0.5668 0.0012 0.0724 0.1415 0.1209 0.4526 0.2734 0.4332 0.5831 0.1515 0.8478
*ADA rs6031682 0.5166 0.6123 0.6101 0.0052 0.9578 0.0016 0.8837 0.8085 0.6321 0.0048 0.8196 0.0019
*ADA rs427483 0.6597 0.8842 0.3286 0.2509 0.1948 0.7039 0.4568 0.3370 0.2699 0.0018 0.0137 0.0063
DNMT3A rs7560488 0.1538 0.0021 0.6359 0.8325 0.8348 0.8823 0.5544 0.3633 0.3848 0.7779 0.9764 0.6509
*CUBN rs2273737 0.5067 0.7062 0.5487 0.0780 0.3584 0.0936 0.4034 0.4843 0.1971 0.0021 0.2034 0.0026
MTHFD1 rs2236225 0.1505 0.9554 0.0257 0.2570 0.3372 0.3869 0.8915 0.6549 1.0000 0.0139 0.2593 0.0022
*T rs10806845 0.2894 0.3889 0.4518 0.0830 0.0370 0.4302 0.2438 0.1204 0.2378 0.0033 0.0023 0.0701
FOLH1 rs383028 0.2073 0.4975 0.2542 0.0050 0.3617 0.0051 0.1033 1.0000 0.0359 0.0054 0.9171 0.0024
*CUBN rs1801222 1.0000 0.5013 0.4017 0.1514 0.7600 0.0181 0.2822 0.1682 0.2448 0.0091 0.1439 0.0024
*ADA rs6094017 0.2199 0.6211 0.2009 0.3960 0.8060 0.3126 0.7449 0.5105 0.5466 0.0026 0.0479 0.0046
*ARID1A rs11247593 0.0154 0.0502 0.0747 0.0027 0.0090 0.0265 0.1455 0.4060 0.1491 0.0615 0.0458 0.5659
COMT rs174675 0.0795 0.7444 0.0028 0.8722 0.5266 0.4898 0.9321 0.7778 0.7457 0.3665 0.2494 0.9574
*ENOSF1 rs1059384 0.6886 0.3493 0.9141 0.0333 0.0028 0.2734 0.9279 0.8084 0.8226 0.0848 0.0063 0.4655
*GART rs4817580 0.0029 0.9996 0.0042 0.0849 0.9745 0.1174 . 0.9996 0.9223 0.4818 0.9747 0.6024
*DNMT3B rs6058896 0.0029 0.0052 . 0.0167 0.0244 0.9744 . 0.2022 . 0.0905 0.1265 0.9744
MTHFD1L rs12199063 0.2857 0.3198 0.5830 0.1248 0.3647 0.0575 0.0855 0.0437 0.7457 0.0035 0.0029 0.1898
MTHFD1L rs6923486 0.1738 0.3458 0.1249 0.1348 0.1283 0.5396 0.2973 0.2651 0.1785 0.0030 0.0090 0.0348
COMT rs737865 0.0112 0.0149 0.1106 0.5284 0.3462 0.2354 0.1983 0.1326 0.1587 0.0852 0.0031 0.5815
*MTR rs10925260 0.0290 0.0031 0.9246 0.6329 0.4355 0.8813 0.4513 0.7071 0.2073 0.1865 0.2408 0.3423
*ADA rs452159 0.0577 0.5282 0.0047 0.7260 0.9583 0.4298 0.1675 0.0627 0.3633 0.0059 0.0578 0.0032
TFAP2A rs17635655 0.8108 0.6367 0.7196 0.0116 0.0236 0.0813 0.1688 0.0876 0.8527 0.0037 0.0075 0.0645



















Table 3 p-values for Evaluated SNPs Showing Association (p < 0.01) with NTDs (Continued)
MTHFD1L rs2295083 0.6044 0.2928 0.2330 0.0168 0.0038 0.7292 0.2734 0.1752 0.5943 0.0558 0.0342 0.7136
*PEMT rs16961845 0.5691 0.4101 0.2719 0.4982 0.4864 0.9363 . 0.0082 . 0.0072 0.0048 0.9255
*ALDH1A2 rs7169289 0.1063 0.6803 0.0967 0.0214 0.5178 0.0043 0.4346 0.2067 0.6266 0.0633 0.6737 0.0513
*MTR rs10733117 0.0099 0.4520 0.0043 0.6020 0.7559 0.6099 0.2998 0.1791 0.2388 0.1436 0.3788 0.1542
MTHFD1L rs17080476 0.0233 0.9996 0.0949 0.0070 0.0244 0.0320 . 0.5299 0.9136 0.1357 0.0994 0.2676
MAT2B rs17535909 0.0102 0.0045 0.5083 0.2745 0.1949 0.7860 0.2061 0.3321 0.2406 0.8030 0.6685 0.8863
GNMT rs9462856 0.0601 0.9187 0.0048 0.7463 0.7773 0.3914 0.8419 0.5788 1.0000 0.6497 0.8424 0.5744
*CTH rs12733999 0.1546 0.1603 0.7406 0.0051 0.0048 0.6384 . 0.1477 0.3414 0.0167 0.0285 0.1264
CDKN2A rs7041637 0.4033 0.0881 0.3011 0.0048 0.0067 0.1269 0.3323 0.2793 0.1978 0.1369 0.3445 0.0716
*RAI1 rs9914733 0.2215 0.1984 0.4266 0.8834 0.4610 0.6300 0.0980 0.6952 0.0320 0.0133 0.8111 0.0049
*FTCD rs2839127 0.2296 0.0301 0.7043 0.8551 0.2725 0.8462 0.0195 0.2266 0.0053 0.1576 0.0483 0.3997
PDGFRA rs9993187 0.3615 0.0802 0.7374 0.0639 0.1576 0.0123 0.4850 0.4235 0.2999 0.0083 0.8603 0.0054
MTHFD1L rs4869987 0.1603 0.6351 0.0458 0.1693 0.2368 0.2939 0.0284 0.3579 0.0511 0.0167 0.1767 0.0061
*ARID1A rs11247594 0.0376 0.0989 0.1141 0.0059 0.0159 0.0438 0.2152 0.2972 0.3060 0.0758 0.0601 0.5558
*ARID1A rs11247596 0.0059 0.1178 0.0151 0.0570 0.2900 0.0682 0.6110 0.3713 0.8781 0.5223 0.0978 0.9777
FOLH1 rs16906205 0.2509 0.5003 0.3078 0.0993 0.9856 0.0730 . 0.9996 0.0060 0.0160 0.9856 0.0102
*FTCD rs7280485 0.5455 1.0000 0.2928 0.9719 0.9612 1.0000 0.0402 0.2205 0.0796 0.1847 0.9315 0.0062
ENOSF1 rs10502289 0.4050 0.0606 0.9176 0.2608 0.0084 0.8743 0.9012 0.6553 0.8231 0.7398 0.4196 0.9254
*MFTC rs10112450 0.0065 0.0154 0.1380 0.1077 0.0765 0.7454 0.4967 0.2680 0.4937 0.5459 0.7307 0.3836
*MFTC rs1865855 0.0339 0.2226 0.0596 0.0066 0.2347 0.0091 0.4858 0.3270 0.3615 0.3489 0.3248 0.2103
MTHFD1 rs11627525 0.7010 0.9468 . 0.7285 0.5723 0.9802 . 0.0067 1.0000 0.5750 0.9194 0.1216
GGH rs11988534 0.0409 0.0067 0.6955 0.2427 0.1156 0.8060 0.6044 0.6257 0.4665 0.9112 0.8775 0.5796
MTHFR rs17037425 1.0000 0.8419 0.6233 0.4158 0.2803 0.6769 0.0149 0.0068 0.7817 0.1828 0.0796 0.4756
MTHFD1L rs487637 0.1946 0.4121 0.0364 0.0162 0.5831 0.0069 0.8861 0.7152 0.8488 0.2125 0.5912 0.2003
DMGDH rs663646 0.2749 0.0070 0.8907 0.7786 0.1838 0.7429 0.8537 0.5782 0.9263 0.5080 0.1877 0.8789
NNMT rs10400393 0.0074 0.1090 0.0203 0.8395 0.6189 0.9926 0.9369 0.7317 1.0000 0.5062 0.4840 0.6355
*CUBN rs11254375 0.3772 0.5709 0.4612 0.6008 0.1449 0.7839 0.0331 0.6321 0.0097 0.0274 0.0074 0.2404
MTHFD1L rs11155772 0.1876 0.1492 0.8084 0.5140 0.8021 0.2358 0.2306 0.0932 1.0000 0.0126 0.0075 0.5404
ALDH1A2 rs6493978 0.5450 0.0984 0.5323 0.1136 0.6939 0.0308 0.9785 0.9093 0.8399 0.0333 0.4523 0.0076
RAI1 rs11658846 0.2504 1.0000 0.2329 0.1382 0.6534 0.1409 0.3954 0.9994 0.1351 0.0104 0.6431 0.0088
LRP2 rs3914468 0.8840 0.1061 0.1878 0.2044 0.0181 0.7696 0.1386 0.7577 0.0734 0.2555 0.0080 0.9562



















Table 3 p-values for Evaluated SNPs Showing Association (p < 0.01) with NTDs (Continued)
MTHFR rs17367504 0.7868 0.3302 0.9193 0.7251 0.6814 0.5857 0.0174 0.7817 0.0081 0.2908 0.4835 0.1536
*EHMT1 rs7039441 0.4612 0.3106 0.8211 0.9611 0.8037 0.9150 0.0319 0.2588 0.0090 0.0981 0.8608 0.0282
*MFTC rs750606 0.0378 0.7460 0.0220 0.0091 0.3426 0.0090 0.2301 0.0994 0.3619 0.3230 0.3719 0.1578
MTHFD1L rs12524884 0.6841 0.7842 0.6630 0.2910 0.5126 0.1146 0.2320 0.0876 0.7633 0.0094 0.0142 0.1789
*RAI1 rs11654526 0.1373 0.0904 0.3348 0.9082 0.6677 0.7709 0.1313 0.4417 0.0450 0.0099 0.2692 0.0106
* Indicates SNP was genotyped in the full cohort (570 triads, 999 controls). Otherwise SNP was genotyped in the primary sample set (320 triads, 341 controls).
** (.) = Failure to converge (no result).



















Figure 2 Linkage Disequilibrium Relationships Between SNPs Significantly Associated with NTDs. Sixty-eight SNPs were associated with
case or maternal effects (p < 0.01, uncorrected). Of these, 56 SNPs occur in the same gene as at least one other significantly associated SNP. Their
D’ (red scale) and r2 (gray scale) relationships are shown. These SNPs are plotted by relative position. Haplotype blocks defined by a Solid Spine of
LD (D’) are outlined in black. Each SNP is numbered and the gene and dbSNP accession number for each are: 1) MTHFR_rs17367504; 2)
MTHFR_rs17037425; 3) ARID1A_rs11247593; 4) ARID1A_rs11247594; 5) ARID1A_rs11247596; 6) MTR_rs10733117; 7) MTR_rs10925260; 8)
CUBN_rs11591606; 9) CUBN_rs1801222; 10) CUBN_rs11254375; 11) CUBN_rs7070148; 12) CUBN_rs2273737; 13) FOLH1_rs383028; 14)
FOLH1_rs16906205; 15) MTHFD1_rs11627525; 16) MTHFD1_rs2236225; 17) ALDH1A2_rs7169289; 18) ALDH1A2_rs6493978; 19) PEMT_rs4646402;
20) PEMT_rs1108579; 21) PEMT_rs16961845; 22) PEMT_rs11656215; 23) RAI1_rs11654526; 24) RAI1_rs9914733; 25) RAI1_rs11658846; 26)
ENOSF1_rs1059384; 27) ENOSF1_rs10502289; 28) ADA_rs6031682; 29) ADA_rs452159; 30) ADA_rs406383; 31) ADA_rs2299686; 32) ADA_rs427483;
33) ADA_rs6094017; 34) GART_rs2070388; 35) GART_rs4817580; 36) FTCD_rs7280485; 37) FTCD_rs2839127; 38) COMT_rs737865; 39)
COMT_rs174675; 40) PDGFRA_rs2114039; 41) PDGFRA_rs9993187; 42) MTHFD1L_rs2295083; 43) MTHFD1L_rs17080476; 44) MTHFD1L_rs487637;
45) MTHFD1L_rs6923486; 46) MTHFD1L_rs12524884; 47) MTHFD1L_rs11155772; 48) MTHFD1L_rs12199063; 49) MTHFD1L_rs4869987; 50)
MFTC_rs10112450; 51) MFTC_rs1865855; 52) MFTC_rs17803441; 53) MFTC_rs750606; 54) MFTC_rs3134260; 55) CDKN2A_rs7041637; 56)
CDKN2A_rs3218009.
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Table 4 The Ten Independent* Association Signals Exhibiting the Lowest Uncorrected p-values for Any Test of NTD
Association
Gene/SNP Risk Allele Frequency** Cohort*** Model OR 95% CI (LL) 95% CI (UL) P
1 MFTC
rs17803441 0.07 Combined LR CC Continuous 1.61 1.23 2.08 0.0003
MFTC
rs3134260 0.07 Combined LR CC Continuous 1.56 1.22 2.04 0.0006
2 CDKN2A LL Maternal effect,
rs3218009 0.13 Primary Dominant 2.32 1.45 3.71 0.0004
3 ADA
rs2299686 0.45 Combined LR MC Dominant 1.56 1.22 2.04 0.0005
ADA
rs406383 0.25 Combined LR MC Continuous 1.12 1.58
ADA
rs427483 0.33 Combined LR MC Continuous 1.28 1.10 1.52 0.0018
4 PEMT
rs1108579 0.52 Combined TDT 1.47 1.18 1.82 0.0006
PEMT
rs11656215 0.49 Combined LL Case effect, recessive 1.68 1.24 2.28 0.0008
PEMT
rs4646402 0.57 Combined LL Case effect, dominant 1.67 1.25 2.17 0.0005
5 CUBN
rs7070148 0.90 Combined LR MC Continuous 1.64 1.22 2.17 0.0010
CUBN
rs2273737 0.89 Combined LR MC Continuous 1.54 1.18 2.04 0.0021
6 GART
rs2070388 0.91 Combined TDT 1.89 1.28 2.78 0.0012
GART
rs2070388 0.91 Combined LL Case effect, dominant 1.96 1.30 2.94 0.0012
7 ADA rs6031682 0.16 Combined LR CC Dominant 1.49 1.16 1.92 0.0016
8 DNMT3A rs7560488 0.42 Primary LL Case effect, recessive 2.10 1.31 3.38 0.0021
9 MTHFD1 rs2236225 0.40 Primary LR MC Dominant 1.96 1.28 3.03 0.0022
10 T (Brachyury) rs10806845 0.51 Combined LR MC Recessive 1.54 1.16 2.00 0.0023
* LD between SNPs within an association signal are as follows: MFTC (D’= 1, r2 = 0.993), ADA (D’> 0.822, r2 > 0.394), PEMT (D’> 0.693, r2 > 0.428) and CUBN
(D’= 0.935, r2 = 0.823). ADA rs6031682 was designated as an independent association signal because it shares very little LD (D’< 0.206, r2 < 0.016) with the other
ADA SNPs (rs2299686, rs406383, rs427483).
**Frequency of the risk allele was calculated using control sample genotypes.
*** Primary: 320 triads, 341 controls. Combined: 570 triads, 999 controls.
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to be associated with maternal risk of carrying an NTD
pregnancy (p ≤ 0.006, uncorrected). Genetic variation in
ADA may contribute to maternal risk of NTDs. In
addition, this gene was the only one to exhibit two inde-
pendent association signals among the top ten signals
observed. This may indicate that there is more than one
allele associated with risk or the same allele has recurred
on more than one haplotype. ADA rs6031682 shows evi-
dence of case effects (p = 0.0016) as well as maternal
effects (p = 0.0019) in log-linear analyses of a dominantmodel, and it is clearly independent of the other signifi-
cant ADA SNPs (D’ < 0.19). It would be of interest to test
the associated ADA SNPs in an independent study, espe-
cially since the scale of correction would be much smal-
ler in a focused study.
PEMT (phosphatidylethanolamineN-methyltransferase)
plays a role in choline metabolism. It converts phos-
phatidylethanolamine to phosphatidylcholine in the liver;
phosphatidylcholine is a major component of cell mem-
branes. This role for choline can compete with its role
as a methyl donor. Choline can be converted to betaine,
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independent conversion of homocysteine to methionine.
This link between folate and choline metabolism makes
PEMT an interesting candidate gene, and interactions
between PEMT SNPs have been reported to be asso-
ciated with NTDs. In a case–control study, single SNP
effects were not observed, although some compound
genotypes for PEMT rs7946 and PEMT rs897453 were
associated with decreased NTD risk [40]. The latter vari-
ant was not directly tested in the current study, and no
association for PEMT rs7946 was observed in this Irish
sample [37]. However, one related SNP pair (r2 = 0.80)
and two other SNPs (r2 < 0.60) in PEMT falling in the
same haplotype block (D’ ≥ 0.69) showed NTD associ-
ation (p < 0.0053, uncorrected) in the current study, sug-
gesting a role for this gene in NTD risk. Unlike the
other three SNPs that exhibited case effects, the least
related SNP in this block (PEMT rs16961845, 0.69 ≤
D’ ≤ 0.89) was positive for maternal effects by three tests
of association. This intronic SNP is in strong r2 LD with
6 other intronic SNPs, making it difficult to speculate
about its function. It is also difficult to discern whether
the associated SNPs in this block represent independent
signals for case risk and for maternal risk, or whether a
single signal for a case effect is being detected. There-
fore, further studies on the variation of this gene and
NTDs are warranted.
MFTC (mitochondrial folate transporter/carrier,
SLC23A32) transports folate from the cytoplasm into the
mitochondria. Some folate metabolic reactions occur in
both the cytoplasm and in mitochondria via
compartment-specific enzymes. The mitochondrion pro-
duces the majority of the one carbon units used by the
cell (reviewed in [41]). As the genes coding for these
mitochondrial enzymes have been identified, they have
been shown to be intriguing and relevant candidates for
NTD studies. For example, we previously reported that
the gene encoding 5, 10-methylene-tetrahydrofolate de-
hydrogenase 1-like (MTHFD1L) contains a polymorph-
ism associated with NTDs [27]. Genetic variation
affecting mitochondrial folate transport may also con-
tribute to NTDs, as seen by our finding that 5 of 11
tested MFTC SNPs showed association (p < 0.01) with
NTD risk in cases. This gene falls in a region of very
high D’ LD; the haplotype block containing these five
SNPs extends ~92 kb and contains two other genes:
DCAF13 (DDB1 and CUL4 associated factor 13) and
CTHRC1 (collagen triple helix repeat containing 1). Any
SNP in this large haplotype block could be the causative
variant driving the observed associations. As the only
coding SNP in MFTC, the best candidate is rs17803441
(R117H). However, as arginine and histidine are both
polar, basic amino acids, this is a fairly conservative
change. We observed a minor allele frequency of 0.07 inthis study. Conservation of the more common arginine
residue is observed in chimp, wolf, cow, mouse, rat and
zebrafish, but not in chicken or invertebrates. All of the
SNPs in high LD (r2 > 0.7) with MFTC rs17803441
(R117H) in this block are intronic or intergenic. This
SNP also had the lowest p-value for any test of associ-
ation of all SNPs tested in this study. It would be of
great interest to determine in an independent population
whether it contributes to NTD risk.
CUBN encodes the intestinal receptor responsible for
the uptake of the vitamin B12-intrinsic factor complex.
It is also expressed in the kidney, where it is involved in
reabsorption of many proteins and vitamins, including
vitamin B12. This gene spans more than 300 kb of DNA.
The only reported SNP association in CUBN is for
rs1907362, which was associated with case risk in a
Dutch population [35]. In contrast, we observed two
highly significant SNPs in CUBN (rs7070148 and
rs2273737) associated with maternal NTD risk. Due to
their high LD these SNPs represent a single association
signal. There were three other highly associated
(p < 0.01) SNPs in this gene. CUBN rs11591606 was
associated with maternal risk, and is in a smaller haplo-
type block at the 3’ end of the gene. Two other CUBN
SNPs (rs1801222 [S253F] and rs11254375) were also
highly associated (p < 0.01) with maternal risk and are in
the same ~30 kb haplotype block with rs7070148 and
rs2273737 at the 5’ end of the gene. While there are
many SNPs in this block that could be the causal risk
SNP, rs1801222 is of interest since it is a coding SNP
(S253F) that was significantly associated with lower
serum vitamin B12 levels in a meta-analysis of three
genome wide association studies of three Caucasian
populations [42]. This does not prove that CUBN
rs1801222 is the causal SNP in either study, but it is
consistent with the hypothesis that this SNP or another
CUBN polymorphism linked to it within this haplotype
block lowers vitamin B12 levels and thereby increases
risk of an NTD pregnancy.
Multiple highly significant SNPs in ADA, PEMT, MFTC
and CUBN account for half of the ten strongest associ-
ation signals observed. The remaining five association sig-
nals are equally compelling. MTHFD1 rs2236225 (R653Q)
was previously reported as a maternal NTD risk factor in
the current study population [23,25] and others [22,24],
while the other four signals represent new associations.
First, CDKN2A rs3218009 was associated with maternal
risk for NTDs. CDKN2a is a tumor suppressor gene that
codes for several isoforms, including ARF (alternate open
reading frame), a protein that stabilizes p53. A subset of
mice carrying p53 null alleles exhibit overgrowth of neural
tissue, supporting the importance of this pathway in nor-
mal neural tube development. Second, the same highly
significant p-value was obtained for GART rs2070388 by
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dominant model of case effect. GART is a trifunctional
enzyme (phosphoribosylglycinamide formyltransferase,
phosphoribosylglycinamide synthetase, phosphoribosyla-
minoimidazole synthetase) involved in de novo purine
synthesis. For its phosphoribosylglycinamide activity,
GART uses N10-formyl tetrahydrofolate as a one-carbon
donor in the synthesis pathway of inosine monopho-
sphate (IMP), a purine precursor. Interestingly, GART
rs4817579 in intron 2 has been associated with cleft lip
and/or palate plus dental anomalies [43]. This variant
was not tested in the current study, and the absence of
GART rs2070388 from the HapMap data prevents us
from evaluating the relatedness of these markers.
Third, DNMT3A rs7560488 was associated with NTD
risk in cases. This gene encodes a DNA methyltransfer-
ase involved in de novo methylation during develop-
ment. The folate pathway generates S-adenosyl
methionine, which is used by DNMT3A as a methyl
donor. Fourth, T (Brachyury) rs10806845 was associated
with maternal NTD risk. The T (Brachyury) gene
encodes a transcription factor involved in mesoderm for-
mation and differentiation, and mice null for T (Brachy-
ury) do not survive to term due to a number of
developmental abnormalities, including fusion of the
neural tube to the gut. Although previous studies differ
in whether genetic variation in T (Brachyury) contri-
butes to NTD risk in cases [44-48], our observation may
be the first indication of its contribution to maternal risk
of carrying an affected fetus.
Although no associations remained significant after
conservative adjustment for multiple tests, it remains
very possible that some of the evaluated candidates doTable 5 Significant (Uncorrected) Analyses of SNPs Previously
Gene/SNP MAF* Cohort** Model
MTHFR rs1801133 677 C > T 0.32 Combined LR CC Contin
Combined LR CC Recess
Combined LR CC Domin
Combined LR MC Conti
Combined LR MC Reces
MTHFD1 rs2236225 R653Q 0.46 Primary LR MC Conti
Primary LR MC Domi
Combined LR MC Domi
Primary LL Case effec
Combined LL TDT
Combined LL Case effec
TCblR rs2336573 G220R 0.04 Combined LR CC Domin
*For each SNP, the minor allele was evaluated as the risk allele.
** Primary: 320 triads, 341 controls. Combined: 570 triads, 999 controls.
*** (.) = Failure to converge. Pexact is shown.in fact contribute to NTDs. The scale of our study de-
sign (using twelve tests of association to evaluate 1441
candidate SNPs) could contribute to Type II errors. This
possibility is supported by the fact that of three SNPs
previously reported to be associated with NTDs in this
cohort (MTHFR 677 C>T [49,50], MTHFD1 R653Q
[23,25], TCblR G220R [34]) only one was observed to be
associated in the current study design (Table 5). Only
MTHFD1 R653Q was found to be significantly asso-
ciated in the primary phase of the analysis, which was
performed on approximately half the samples. MTHFR
677 C>T and TCblR G220R were only found to be asso-
ciated (p < 0.05, uncorrected) when the full cohort of
samples were used. This suggests the possibility that the
stringency of correction may be too high. Additionally, it
is important to note that MTHFD1 R653Q was ninth
among the top ten association signals in this study
(Table 4). This suggests that a number of the ten stron-
gest association signals observed in this study play a role
in NTD risk, and they should be high priority candidates
for further study.
Conclusions
In summary, this study involves the largest evaluation of
common genetic variation for NTD risk yet reported:
1441 SNPs in 82 candidate genes. While no SNP asso-
ciations remained significant after correction for mul-
tiple tests, there is a strong possibility that the study
design and/or stringency of correction has resulted in
obscuring true associations. At least one established risk
factor, MTHFD1 R653Q, was corrected away, suggesting
our approach was extremely conservative. Therefore,
variation in the top genes identified in this study shouldReported as NTD Risk Factors in this Population
OR 95% CI (LL) 95% CI (UL) P
uous 1.23 1.05 1.45 0.011
ive 1.26 1.01 1.57 0.041
ant 1.44 1.04 2.00 0.029
nuous 1.22 1.04 1.43 0.017
sive 1.25 1.01 1.57 0.045
nuous 1.35 1.06 1.71 0.014
nant 1.97 1.28 3.04 0.002
nant 1.48 1.14 1.92 0.003
t, dominant 0.53 0.30 0.93 0.026
0.80 0.65 0.99 0.039
t, dominant 0.60 0.42 0.86 0.005
ant .*** 0.013
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especially since many of these genes (MFTC, CDKN2A,
ADA, CUBN, DNMT3A, and T (Brachyury)) represent
new avenues of investigation.
Methods
Study population
The recruitment of the Irish NTD families (cases and
parents) and controls has been described [23,34,51,52].
Briefly, the cohort includes 586 families with an NTD
case; 442 of these families are full family triads (DNA
from case, mother and father). For this study, 570 of the
NTD families had sufficient DNA and were divided into
two sets, one for primary analysis and one for secondary
(combined) analysis. The primary and secondary sample
sets were matched as closely as possible for the following
parameters: the number of complete NTD triads, the
proportion of NTD cases with spina bifida vs. other
NTDs, and NTD case gender (Table 6).
The control population (n = 999) is a random sample
drawn from 56,049 blood samples donated by women at
their first prenatal visit to the three major maternity hos-
pitals in Dublin (1986–1990). A subset of controls
(n = 341) was randomly selected for the primary screen,
and the remaining controls were used in the secondary
set.
Written, informed consent was obtained from study
subjects, their parents or their guardians. Archived con-
trol samples were anonymized prior to analysis. The
study was approved by the Ethics Research Committee
of the Health Research Board (Dublin, Ireland) and the
Institutional Review Board at the National Human Gen-
ome Research Institute (Bethesda, MD, USA). Extraction
of genomic DNA from blood samples and buccal swabs
was performed using the QIAamp DNA Blood Mini Kit
(Qiagen, Valencia, CA, USA).
SNP selection
Genes were chosen for study because they are involved
in folate and vitamin B12 metabolism or other metabolic
and signaling pathways implicated in the etiology of
NTDs (Figure 1). Although previously published,
MTHFR [52-54], MTHFD1 [23,25], MTHFD1L [27],
TCblR [34], and TP53 [51] were reanalyzed in this study
in order to compare the differing research strategy,
which includes new genetic models of risk assessment.
For each gene chosen, we evaluated the transcribed re-
gion of the gene and 10 kilobases (kb) upstream andTable 6 Characteristics of the Irish NTD Sets Used in this Stud
No. Families (%) No. Cases (%)
Primary set 320 (56.1%) 301 (56.8%)
Secondary set 250 (43.9%) 229 (43.2%)downstream of the gene in an effort to include poly-
morphisms with potential proximal effects, such as pro-
moter variants. In order to capture the common
variation in each gene, SNPs genotyped by HapMap
(Data Release 21, Phase II, Anon, 2003 [55]) were con-
sidered. A set of tagSNPs was identified using an algo-
rithm based on optimizing for tagSNPs with maximal
minor allele frequencies (MAFs) and an r2 threshold of
0.8, while maximizing the MAF of the selected tagSNP.
In addition to this set of tagSNPs, validated variants
from dbSNP [26] were also selected for physical cover-
age so that spacing between SNPs would be less than
20 kb within D’ haplotype blocks and less than 5 kb be-
tween haplotype blocks. A total of 1517 SNPs were
selected.
Genotyping
The selected 1517 SNPs were genotyped on the primary
sample sets (320 NTD case families and 341 controls).
Genotypes were generated by the Johns Hopkins Univer-
sity SNP Center (Baltimore, MD) using the Illumina
GoldenGate assay (Illumina, San Diego, CA). Of the
1517 SNPs attempted, 1320 SNPs (87.2%) remained after
filtering out low quality data (re-attempted on another
platform, see below). The overall call rate for these 1320
SNPs was 98%. All but 150 of these SNPs had a call rate
of >95%; the rest had an average call rate of 87.2%
(±7.9%) and were re-genotyped on another platform (see
below). Both the overall duplicate concordance rates and
the Mendelian consistency rates were 99.99% for the
1320 accepted SNPs.
Based on analyses of the primary sample sets, 93 SNPs
were genotyped in the secondary sample set (250 NTD
case families and 658 controls). Genotypes were gener-
ated by KASPar chemistry at Kbiosciences (Herts, UK).
Three SNPs failed on this platform: rs127317149,
rs7367859 and rs7096079. For the 90 successfully geno-
typed SNPs, the overall duplicate concordance rate was
99.81% and the overall Mendelian consistency rate was
99.94%.
SNPs that could not be assayed (n = 197) or returned
low call rates (<95%, n = 150) via Illumina GoldenGate
chemistry were re-genotyped in the entire sample set
(570 NTD families and 999 controls) by detection of
allele-specific primer extension using matrix-assisted
laser desorption/ionization – time of flight (MALDI-
TOF) mass spectrometry (Sequenom, San Diego, CA,
USA). Genotyping data from SNPs with call rates abovey
% Complete Triads % Spina Bifida % Female Cases
75.2% 94.9% 51.8%
73.6% 95.7% 55.3%
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failed and 106/150 SNPs that yielded low call rates). The
overall duplicate concordance rate was 99.10% and the
overall Mendelian consistency rate was 99.32% for these
227 SNPs.
To summarize, our final data set consisted of 1441
SNPs; 1320 high quality SNPs from the Illumina plat-
form (93 of these SNPS were also typed in the secondary
samples using the KASPar platform, and 106 of these
SNPs were re-typed in the entire sample set using the
Sequenom platform) plus 121 SNPs from the Sequenom
platform.Linkage disequilibrium
D’ and r2 measures of LD for SNPs of interest were esti-
mated based on control genotypes using Haploview [56].
Haplotype blocks were based on D’ values using the
Solid Spine of LD option in Haploview.Statistical methods
The design for this study involved two stages of genotyp-
ing. Rather than use the secondary samples for a replica-
tion study, joint analysis of the combined dataset was
performed since it generally provides greater power to
detect a genetic effect [57]. In the initial analysis, all
SNPs successfully typed with the Illumina GoldenGate
assay (n = 1320, including the 150 high quality SNPs with
call rates of <95%) were analyzed in the primary sample
set by four tests of association. Two tests were per-
formed to evaluate case effects: 1) Logistic regression, a
1-degree of freedom (DOF) test of association between
the affected status and number of risk alleles; and 2) the
Spielman transmission disequilibrium test (TDT, [58]).
Similarly, two tests were performed to evaluate maternal
effects: 1) Logistic regression, a 1-DOF test of associ-
ation between the maternal status and number of risk
alleles; and 2) log-linear modeling with 2-DOF to test
for effect of the maternal genotype.
SNPs were selected to be genotyped on all samples
(570 NTD case families and 999 controls) if they met
the following criteria: 1) SNPs of interest reaching a sig-
nificance level in the primary analysis (n = 93, Table 2);
or 2) failed SNPs (n = 121) and SNPs with low call rates
(<95%, n = 106). Final analyses were performed on the
entire dataset and consisted of twelve association tests.
NTD case–control and NTD mother-control compari-
sons were performed using continuous, recessive and
dominant coded models of logistic regression to gener-
ate odds ratios (ORs) and 95% confidence intervals (CI).
Six family-based tests of association were also applied
using log-linear models. The NTD triads (case, mother
and father) were analyzed for case effects using reces-
sive, dominant and linear (TDT) coding while directmaternal effects were analyzed using recessive, dominant
and 2-DOF models.
To correct for multiple comparison, the final analysis
used the complete information on the 1441 SNPs. Cor-
rection was performed by multivariate permutation
(N= 9,999 random permutations) for three of the tests
used in the initial analysis: case–control logistic regres-
sion, mother-control logistic regression and the TDT.
This method accounts for any linkage disequilibrium be-
tween SNPs. Multivariate permuting of triads for the
TDT was performed by treating the test as a one-sample
test and permuting the risk allele [59]. Independent per-
mutations were performed for the cases and controls or
mothers and controls to adjust for multiple comparisons
in the tests of logistic regression. The results were com-
bined by Bonferroni adjustment to account for all com-
parisons (including all SNPs because of our multivariate
permutation approach) while controlling the probability
of any false positives at 5%. Since a SNP could only be
found significant based on this combined analysis, our
method provides type I error control regardless of the
SNP selection process or number of SNPs selected for
genotyping on all samples.
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